A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (SWITCH - ITA)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Study type: Observational

Funder types: Industry

Identifiers

NCT05658601

IM047-1038

Details and patient eligibility

About

The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).

Enrollment: 104 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with RRMS according to 2017 revised McDonald criteria
• Patients who switched a previous first or second line DMT to ozanimod between 4 and 12 weeks before the enrollment
• Patient with a MRI performed within three months before the enrollment
• Patient eligible to ozanimod according to SmPC

Exclusion criteria

• Patients with clinical forms of MS other than RRMS
• Patients unable to participate for various reasons
• Patients participating in another clinical study with an investigational product if the study considers the switching behavior as an endpoint or objective
• Contraindications to ozanimod according to SmPC

Other protocol-defined Inclusion/Exclusion Criteria apply.

Trial design

104 participants in 1 patient group

Cohort 1